Hughes Eric A 4

What Happened

• Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceutical Industries Ltd (TEVA), received an award of 141,478 restricted share units (RSUs) on January 27, 2026. The grant is recorded at $0.00 on the Form 4 because it is a derivative award (not an open-market purchase or sale).
• These RSUs resulted from satisfaction of performance criteria tied to prior performance share units and remain subject to time-based vesting; they are scheduled to vest on March 3, 2026. The filing lists the award as a derivative grant rather than a cash transaction.

Key Details

• Transaction date: 2026-01-27; Form 4 filed: 2026-01-29 (appears timely — within the usual two-business-day reporting window).
• Award: 141,478 restricted share units (RSUs); reported acquisition price: $0.00 (derivative grant).
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 — each RSU is a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share; F2 — these RSUs were issued upon satisfaction of performance criteria and still vest on 3/3/2026; F3 — ordinary shares may be represented by American Depositary Shares (ADS).
• Remarks: Insider role listed as Executive Vice President, Global R&D and Chief Medical Officer.

Context

• This was an equity award (compensation/retention), not a market purchase or sale; such grants are common for executive compensation and do not, by themselves, indicate the insider bought or sold company stock.
• Because these RSUs are derivative awards that vest in the future, they do not convey immediate share ownership until settlement (or cash payment, if elected by the committee).